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Objective: To measure angiogenin, a potent inducer of 
neovascularization and interleukin-6, as an indicator of 
acute inflammation, in second-trimest€I amniotic fluid of 
patients with elevated maternal serum hCG. 
Methods: In this case-control study, 2.0 patients with ele-
vated maternal serum hCG (at least 2.0 multiples of median) 
at triple screen were matched 2:1 with (ontrols on the basis 
of year of amniocentesis, parity, and ra,:e. Inclusion criteria 
were 1) singleton gestation, 2) no evidence of anomalies, and 
3) genetic amniocentesis. Amniotic fluid was immunoas-
sayed for angiogenin and interleukin-6. The immunoassay 
sensitivity for angiogenin was 0.026 ng/ml, interassay coef-
ficient of variation 4.6%, and intra-assay coefficient of vari-
ation 2.9%. For interleukin-6, the immunoassay sensitivity 
was 2.37 pglml, interassay coefficient of variation 2.7%, and 
intra-assay coefficient of variation 1.9%. Angiogenin and 
interleukin-6 values were normalized by using natural log 
transformation for statistical analysis. Statistical analysis 
included analysis of variance and stepwise regression, with 
P < .05 significant. 
Results: After correcting (by multivariate regression) for 
gestational age at sampling and nulliparity, amniotic fluid 
angiogenin levels were significantly lower in the study 
subjects than in controls (26% ± 11% lower, P = .004), 
whereas the interleukin-6 levels did not change significantly 
(34% ± 40% lower, P = .3). 
Conclusion: Amniotic fluid angiogeJllin levels are signifi-
cantly lower in patients with elevated maternal serum hCG 
at triple screen, suggesting inadequate angiogenesis, but 
interleukin-6 values do not differ significantly. (Obstet Gy-
necol 1998;91:605-8. © 1998 by The American College of 
Obstetricians and Gynecologists.) 
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Maternal serum levels of hCG are measured commonly 
as part of a second-trimester genetic screening for 
chromosomal anomalies (triple screen). Pregnant 
women with unexplained elevations of hCG serum 
levels have an increased risk of subsequent preeclamp-
sia, fetal growth restriction, and preterm delivery.1-5 
Multivariate analysis has shown that after controlling 
for preeclampsia, elevated second-trimester hCG levels 
are not predictive of fetal growth restriction or preterm 
delivery, but only of hypertenSive complications.2 The 
link between second-trimester hCG levels and hyper-
tension is unknown presently. 
Experimental evidence suggests that three factors can 
influence production of hCG by the trophoblast. First, 
number of trophoblastic cells (predominantly syncy-
tiotrophoblast) in the placenta is correlated with mater-
nal serum hCG levels.6 Second, the degree of oxygen-
ation of trophoblastic cells has been shown to influence 
hCG production. Studies6 - 8 using cultured villi from 
term placentas found that prolonged low oxygen ten-
sion decreased synthesis and release of hCG compared 
with normoxic conditions; these findings have been 
attributed to a decrease in syncytium formation because 
trophoblast survival was documented by a continued 
ability to synthesize protein and by recovered ability to 
form syncytium and to release hCG once the hypoxic 
conditions were withdrawn. Third, inflammatory cyto-
kines, such as interleukin-6, have been shown to stim-
ulate hCG synthesis in vitro.9 
To establish which process underlies the elevation in 
maternal serum hCG levels, we have measured amni-
otic fluid angiogenin and interleukin-6 in a consecutive 
series of women who underwent genetic amniocentesis 
because of abnormal triple screening and who had 
elevated serum levels of hCG. Interleukin-6 is an in-
flammatory cytokine, and elevations of interleukin-6 
concentration in amniotic fluid have been associated 
with intrauterine infection. lO Angiogenin is a potent 
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inducer o:f neovascularization and a known marker of 
ischemia in several tissues including placenta.9 
Materials and Methods 
In this case-control study, 20 women with elevated 
maternal serum hCG (at least 2.C multiples of the 
median) who underwent genetic amniocentesis were 
compared with 40 controls chosen to be as comparable 
as possible, in the aggregate, in year of amniocentesis, 
race, and parity. Patients underwent amniocentesis at 
Georgetown University Medical Ce:,ter, University of 
Utah School of Medicine, or Utah Valley Regional 
Medical Center between May 1993 and August 1996. 
Inclusion criteria were singleton gestation, gestational 
age of 15-24 weeks at amniocentesis, no evidence of 
fetal structural or chromosomal anomalies, and genetic 
amniocentesis. Gestational age was confirmed or estab-
lished by ultrasonographic fetal biometry at time of 
amniocentesis (before 25 weeks' ge:,tation). Small for 
gestational age was defined as birth weight less than the 
10th percentile for gestational age. l1 •12 Demographic 
data including gestational age at amniocentesis and 
delivery, pregnancy complications including prelabor 
rupture of membranes, chorioamnionitis, preterm la-
bor, and neonatal birth weight were collected by chart 
review. 
Angiogenin and interleukin-6 levels were measured 
by enzyme-linked immunosorbent assay (ELISA) (R&D 
Systems, Minneapolis, MN) validated for amniotic 
fluid. Samples were assayed in duplicate in a single 
batch. The angiogenin ELISA limit of detection for 
amniotic fluid was 0.026 ng/mL, and the inter- and 
intra-assay coefficients of variation were 4.6')10 and 2.9%, 
respectively. The angiogenin ELISA used is specific for 
angiogenin and does not cross-react or interact with 
human interleukin-la, -1{3, -2, -3, -4, -6, -7, or -8 or 
tumor necrosis factor a or {3. The ELlSA sensitivity for 
interleukin-·6 was 2.37 pg/mL, interassay coefficient of 
variation 2.7%, and intra-assay coefficient of variation 
1.9%. The ELISA used for interleukin-6 does not cross-
react or interact with recombinant human interleukin-
la, -1{3, -3, -4, -7, or -8 or tumor necrosis factor-a or -{3. 
Statistical analysis included .i and Fisher exact test 
for categoric variables, one-way analysis of variance for 
continuous variables, Mann Whitney il test for data not 
distributed normally, and stepwise regression analysis 
with P < .05 considered significant (Statview 4.5; Aba-
cus Concepts Inc., Berkeley, CA). Angiogenin and in-
terleukin-6 levels were normalized with natural log 
transformation for statistical analysiS. Stepwise regres-
sion was used as part of the model-building process to 
eliminate variables that either had no effect or that 
influenced the outcome only indirectly, by virtue of 
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Table 1. Obstetric Characteristics 
Elevated 
hCG 
Patient population 11 ~ 20 
Maternal age (y) 29.3:+: 7.9 
Race 
White 18 (90%,) 
Black 1 (5°;,,) 
Other 1 (5%) 
Nulliparous 11 (55%) 
GA at sampling (wk) 19.4 :+: 3.5 
GA = gestational age. 
Control 
11 ~ 40 











Dala are presented as mean:+: standard deviation or 11 ("!o). 
their correlation with other variables that were related 
more strongly to outcome. This study was approved by 
the Institutional Review Board committees at George-
town University Medical Center, University of Utah 
School of Medicine, and Utah Valley Regional Medical 
Center. 
Results 
Twenty gravidas with elevated hCG values were 
matched with 40 controls. Gestational age at sampling 
and maternal age were significantly different between 
the two groups, reflecting that patients with abnormal 
screening undergo amniocentesis at a later gestational 
age than those with advanced maternal age. Similarly, 
because patients with normal screening tests do not 
undergo amniocentesis, controls are represented pri-
marily by patients undergoing amniocentesis for ad-
vanced maternal age. As a consequence, the rate of 
nulliparity also was significantly different between the 
two groups. Maternal race was not different between 
the groups (Table 1). 
Neonatal birth weight, delivery type, gender of the 
infant, and Apgar scores less than 7 were not different 
between the two groups. Three study patients delivered 
before 37 weeks' gestation, compared with two in the 
control group (P = .3). In addition, three patients with 
elevated hCG levels delivered small for gestational 
infants, compared with three controls (P = .9). The rate 
of preeclampsia was not different between the groups 
(Table 2). 
Angiogenin and interleukin-6 were detected in all 
samples of amniotic fluid. After correcting (via multi-
variate regression) for gestational age at sampling and 
nulliparity, amniotic fluid angiogenin levels were sig-
nificantly lower in the study patients compared with 
the controls (26% :±: 11% lower, P = .004), whereas the 
interleukin-6 levels did not change significantly (34% :±: 
40% lower, P = .3). All covariates in the multiregression 
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Table 2. Pregnancy Outcome 
Elevated 
hCG Control 
(n = 20) (n = 40) P 
GA at delivery (wk) 37.9 ::':: 5.7 39.3 ::':: 1.6 .005 
Vaginal delivery 16 (80%) 30 (75'10) .4 
Birth weight (g) 3037 ::':: 645 3330::':: 577 .08 
SGA < 5th percentile 3 (15%) 3 (8'1.,) .9 
Female gender 10 (50%) 18 (45%) .8 
5-min Apgar <: 7 3 (15%) 1 (3%) .1 
Preeclampsia-eclampsia 2 (10%) 4 (10%) .9 
Preeclampsia causing PTD 2 (10%) 0 .1 
PTD « 37 wk) 3 (15%) 2(5%) .3 
GA = gestational age; SGA = small for gestational age; PTD = 
preterm delivery. 
Data are presented as mean ± standard deviation or n (%). 
analysis for angiogenin were significant, and no vari-
ables were forced into the analysis. 
Discussion 
Our intent in undertaking this study was to determine 
which process underlies the elevation of maternal se-
rum hCG in the second trimester. We used two amni-
otic fluid cytokines-angiogenin and interleukin-6-as 
markers of the two pathophysiologic processes that 
could be involved in hCG elevation: placental ischemia 
and inflammation, respectively. We have found that 
amniotic fluid angiogenin levels are significantly lower 
in patients with elevated serum levels of hCG at triple 
screen, after controlling for maternal age, gestational 
age at sampling, nulliparity, and year of amniocentesis. 
We used stepwise regression analysis to account for the 
confounding variables that were present inevitably be-
tween the study and control groups, given the design of 
the study, and that could not be prevented by improved 
matching criteria. Indeed, becausE' abnormal serum 
screening and advanced maternal age are the most 
common indications for early second-trimester amnio-
centesis, it is difficult to match patients for maternal age 
and parity. 
We did not find evidence of an association between 
maternal serum hCG elevation and amniotic fluid in-
flammatory cytokine levels, such as interleukin-6. This 
lack of association cannot be ascribed to a lack of effect 
of interleukin-6 on cytotrophoblast, because studies 
have shown that inflammatory cytokines, including 
interleukin-6 or -1 and TNF-a, are involved in hCG 
release by normal human trophoblast. Interleukin-6 
receptors are present on trophoblastic cells and the 
presence of a cytokine-mediated regulatory network of 
hCG release by trophoblast has been documented.9•13 
At a significance level of .05, the power of detecting an 
effect of the size we observed is 18%. To obtain a 
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significant result with this size effect would require 75 
patients with elevated hCG levels and 150 control 
patients. 
Our observation of low levels of amniotic fluid an-
giogenin in cases with elevated maternal serum hCG 
levels sheds some light on the intrauterine processes 
that occur during the early second trimester. Events 
critical to appropriate placental vascular development 
are known to occur beginning around 15 weeks' gesta-
tion. A second wave of trophoblast invasion into the 
spiral arteries is associated with subsequent conversion 
of the spiral arteries into uteroplacental arteries. Direct 
observations of this crucial period are lacking because 
of the lack of access to placental tissue from ongoing 
pregnancies. We postulate that the low amniotic fluid 
angiogenin levels we have found signal inadequate 
placental angiogenesis and neovascularization, two 
processes that are required for normal placental devel-
opment. As a result, placental ischemia (ie, decreased 
perfusion) ensues, to which the trophoblast responds 
typically by proliferation. The hyperproliferative isch-
emic trophoblast would manifest by increased hCG 
secretion. 
Supporting this hypothesis is the observation that 
preeclampsia, the pregnancy complication associated 
most commonly with second-trimester hCG elevation, 
is characterized histologically by exaggerated tropho-
blast proliferation at the implantation site. Because this 
trophoblastic proliferation also is associated with fail-
ure of the trophoblast to invade the myometrial spiral 
arteries progressively and to convert them into large 
capacitance vessels, a more generalized maturation 
defect in the trophoblast may be taking place during the 
early second trimester in pregnancies destined to de-
velop preeclampsia. 14 Indeed, complete or partial ab-
sence of physiologic conversion of the spiral arteries is 
the most outstanding of the uteroplacental findings 
associated with preeclampsia. Our MEDLINE search 
(1966-1996) using as search terms hCG, ischemia, hyp-
oxia, and placenta identified no publications on his-
topathologic placental findings in women with elevated 
second-trimester serum hCG levels. Because not all 
patients with elevated second-trimester hCG levels pro-
ceed to develop preeclampsia, other factors or variables 
must play a role. The low rate of preeclampsia-
eclampsia in our study and control groups, probably 
due to our small sample size, prevents us from drawing 
any meaningful conclusion to this end. A sample about 
twice the size of ours would be required to detect a 
significant difference in the incidence of preeclampsia-
eclampsia between the two groups. Moreover, the lack 
of histopathologic placental documentation in our 
study does not allow correlations between second-
trimester serum and amniotic fluid findings and under-
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lying pathologic processes, as documented by placental 
findings. Larger studies are necessary to correlate lab-
oratory findings (hCG and amniotic fluid angiogenin 
levels) with both clinical (preeclampsia) and his-
topathologic (placental) findings. 
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